<DOC>
	<DOCNO>NCT01332240</DOCNO>
	<brief_summary>As use endoscopic ultrasonography mediastinal diagnosis and/or stag widely spread Belgium , investigator aim determine number mediastinoscopies need detect one additional mediastinal lymph node invasion routine clinical practice stag potentially resectable clinical stage III non-small cell lung cancer .</brief_summary>
	<brief_title>External ValidatIon Trial ASTER Trial</brief_title>
	<detailed_description>Background : The observation make ASTER investigator might criticize procedure perform highly experienced center . To date , number mediastinoscopies need detect one additional N2/3 disease routine clinical practice chest physician perform endosonography mediastinal stag unknown . The investigator therefore seek answer whether negative endosonography routinely follow mediastinoscopy day day clinical practice . Aim : As use endoscopic ultrasonography mediastinal diagnosis and/or stag widely spread Belgium , investigator aim determine number mediastinoscopies need detect one additional mediastinal lymph node invasion routine clinical practice . Setting : center Belgium EBUS-TBNA and/or EUS-FNA experience least 20 patient agree participate include patient . Design : Prospective national observational multicenter study . All patient clinical N2/3 disease base CT and/or PET require invasive mediastinal stag primarily undergo invasive mediastinal staging endosonography ( EBUS +/- EUS ) . A subsequent cervical mediastinoscopy perform case mediastinal lymph node involvement find endosonography . Local surgeon perform procedure accord institutional practice . Thoracotomy mediastinal lymph node dissection gold standard invasive mediastinal staging , case mediastinal lymph node metastases find clinical stag include endosonography mediastinoscopy . Patients : The study include 255 patient , base calculation 15 consecutive patient participate center , order validate ASTER data . Primary endpoint : The number mediastinoscopies need detect one additional N2/3 . Secondary endpoint : The number mediastinal lymph node station sample endosonography ; median size large mediastinal lymph node sample ; characteristic mediastinal nodal disease miss endosonography .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Consecutive patient ( suspect ) NSCLC invasive mediastinal staging require base presence ACCP group B mediastinal lymph node and/or FDGPET positive ( visual interpretation FDG uptake mediastinal node present ) mediastinal lymph node ( either ACCP group B ACCP group D ) lymph node station 2 , 4 , 7 , 8 9 ( see Appendix ) . Potentially operable resectable disease . Radically treat previous extrathoracic malignancy allow whenever extrathoracic malignancy consider remission , primary parenchymal lung tumour present . Provision write informed consent . Previous cervical mediastinoscopy . Uncorrected coagulopathy . Former treatment lung cancer . Patient unable give write informed consent . Absence primary parenchymal lung tumour . Distant metastasis ( cM1 disease ) routine clinical workup . Clinical N2/3 disease base suspected mediastinal lymph node station 5 6 . Patients belong ACCP group A C base CT scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>stag</keyword>
	<keyword>endosonography</keyword>
	<keyword>lung cancer</keyword>
	<keyword>stage III</keyword>
</DOC>